SAB Biotherapeutics’ Immunotherapy Proposal Among Top Platform Technology Solutions In Recent WHO Report

SAB Biotherapeutics’ Immunotherapy Proposal Among Top Platform Technology Solutions In Recent WHO Report

September 20, 2016

SAB Biotherapeutics Receives $1.42 Million SBIR Grant To Advance Influenza Treatment

September 7, 2016
SAB Biotherapeutics Announces Contract With BARDA To Advance First MERS Treatment

SAB Biotherapeutics Announces Contract With BARDA To Advance First MERS Treatment

August 24, 2016

Phase I Clinical Trials Underway For First MERS Treatment

August 11, 2016
New Study By University Of Maryland School Of Medicine Researchers Finds Promising Results For Treatment

New Study By University Of Maryland School Of Medicine Researchers Finds Promising Results For Treatment

February 17, 2016
SAB Biotherapeutics Produces New Human Antibody Treatment For MERS-CoV

SAB Biotherapeutics Produces New Human Antibody Treatment For MERS-CoV

February 17, 2016

Internationally Recognized Experts Appointed To SAB Biotherapeutics Scientific Advisory Board

January 19, 2016
Development Foundation Invests In Growing SAB Biotherapeutics

Development Foundation Invests In Growing SAB Biotherapeutics

January 6, 2015
SAB Biotherapeutics And U.S. Army Team Up To Treat Hantavirus

SAB Biotherapeutics And U.S. Army Team Up To Treat Hantavirus

December 3, 2014
Human Antibodies Produced In DNA-Vaccinated Cows Protect In Lethal Models Of Hantavirus Pulmonary Syndrome

Human Antibodies Produced In DNA-Vaccinated Cows Protect In Lethal Models Of Hantavirus Pulmonary Syndrome

November 26, 2014